<DOC>
	<DOCNO>NCT02733380</DOCNO>
	<brief_summary>This prospective phase II clinical trial observe efficacy safety Chidamide combine VDDT ( vinorelbine，liposomal doxorubicin，dexamethasone thalidomide ) relapse refractory patient diffuse large B-cell lymphoma ( DLBCL ) .</brief_summary>
	<brief_title>Chidamide Combined With VDDT Regimen Relapse Refractory Diffuse Large B Cell Lymphoma</brief_title>
	<detailed_description>There one third diffuse large B-cell Lymphoma patient suffer relapse refractory , major cause death among patient . Vinorelbine，liposomal doxorubicin，mitoxantrone , dexamethasone thalidomide use therapy patient fail Second-line treatment center . This regimen well tolerated effect need improve . Chidamide，a histone deacetylase inhibitor approve treatment refractory T-cell lymphoma China . The goal ass efficacy safety chidamide combine VDDT（vinorelbine，liposomal doxorubicin，dexamethasone thalidomide） relapse refractory patient diffuse large B-cell Lymphoma .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<criteria>1 . Diagnosed diffuse large Bcell Lymphoma base 2008 WHO classification tumor haematopoietic lymphoid tissue 2 . Failed secondline therapy 3 . Having least one measurable lesion 4 . Age 18 75 year old 5 . World health organizationEastern Cooperative Oncology Group Performance Status ( ECOG ) 01 6 . Neutrophils 1.5*10^9/L ; Platelets 90*10^9/L Hemoglobin : 90g/L . 7 . Life expectancy le 3 month 8 . No receive chemotherapy 4 week enrollment 9 . Agreeing sign write informed consent 1 . Pregnant ，lactating patient reproductive age refuse practice contraception 2 . QTc prolong ＞450ms，ventricular tachycardia，atrial fibrillation，cardiac conduction block， myocardial infarction le 1 year， congestive heart failure，coronary heart disease need medication . 3 . Organ transplant recipient 4 . Active bleed 5 . Thrombus，embolism，cerebral hemorrhage，cerebral infarction 6 . Important organ operation le 6 week 7 . Abnormal liver function（Note：total bilirubin ＞1.5 time upper limit normal，AST ALT ＞2.5 time upper limit normal （Note：5 time upper limit normal patient liver involvement）），abnormal renal function（Note：serum creatinine ＞1.5 time upper limit normal），fluid electrolyte disorder 8 . Mental illness unable sign inform consent 9 . Drug addiction history alcoholism may interfere experimental result . 10 . Researchers determine unsuited participate trial 11 . Known allergy kind study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Diffuse Large B-Cell Lymphoma</keyword>
	<keyword>Relapsed refractory</keyword>
	<keyword>Histone deacetylase inhibitor</keyword>
	<keyword>Chidamide</keyword>
</DOC>